The authors also investigated the response to the BTK inhibitor (ibrutinib) treatment in the model and found that both CLL cell line and primary CLL cells migrated outside the scaffold after treatment to a much higher extent than the untreated control, confirming that drug treatment influences cell mobilization [169]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.